GlassScriptPhysician profile
Jessica Franklin
NPI 1730620816
$4,951.33
in general payments reported to CMS, 2019-2025
28 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $278 · 2023: $1,516 · 2024: $1,756 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,658 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,658.46 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.54 | 2022-2025 | |
| Alkermes, INC. | $385.30 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.61 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $312.74 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $309.44 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $250.15 | 2024-2025 | Spravato |
| Gilead Sciences, INC. | $199.73 | 2023 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $181.46 | 2024 | Airsupra, Breztri |
| Organon LLC | $160.51 | 2022-2025 | Nexplanon |
| Inspire Medical Systems, INC. | $159.38 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $141.82 | 2024-2025 | Uzedy |
| Xeris Pharmaceuticals, INC. | $140.43 | 2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $130.28 | 2024-2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $125.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $100.58 | 2023-2025 | Rexulti, Abilify Maintena |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $98.20 | 2023 | |
| Alexion Pharmaceuticals, INC. | $95.23 | 2023 | Soliris |
| Vanda Pharmaceuticals INC. | $81.36 | 2024-2025 | Fanapt |
| Neurelis, INC. | $73.17 | 2023 | Valtoco |
| Glaxosmithkline, LLC. | $59.17 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Neurocrine Biosciences, INC. | $53.80 | 2023-2024 | Ingrezza |
| Medtronic, INC. | $23.41 | 2023 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.24 | 2025 | Caplyta |
| Corcept Therapeutics | $19.01 | 2025 | Korlym |
| Braeburn INC. | $17.91 | 2025 | Brixadi |
| Amgen INC. | $17.71 | 2023 | Evenity, Prolia |
| Indivior INC. | $16.45 | 2025 | Sublocade |
| Lundbeck LLC | $15.70 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.